ABC 294640

Drug Profile

ABC 294640

Alternative Names: ABC-294640; YELIVA

Latest Information Update: 19 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Apogee Biotechnology Corporation
  • Developer Apogee Biotechnology Corporation; Louisiana State University Health Sciences Center; Medical University of South Carolina; RedHill Biopharma
  • Class Adamantanes; Antineoplastics; Pyridines; Small molecules
  • Mechanism of Action Sphingosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Phase II Hepatocellular carcinoma
  • Phase I/II Diffuse large B cell lymphoma; Kaposi's sarcoma; Multiple myeloma
  • Phase I Solid tumours
  • Preclinical Cholangiocarcinoma; Inflammatory bowel diseases; Osteoarthritis; Prostate cancer; Radiation injuries; Rheumatoid arthritis

Most Recent Events

  • 13 Apr 2017 Chemical structure information added
  • 04 Apr 2017 ABC 294640 receives Orphan Drug status for Cholangiocarcinoma in USA
  • 04 Apr 2017 RedHill Biopharma plans a phase IIa trial for Cholangicarcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top